Rule 3.19A.2

# Appendix 3Y

## **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Noxopharm Limited (ASX:NOX)
ABN:	50 608 966 123

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Graham Kelly
Date of Last Notice:	18 August 2016

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change	- 19 Decem	ıber 2016	
No. of securities held prior to change	 		
real prior to enange		Shares	Options
	Direct	35,000	-
	Indirect	24,345,000	12,075,000
	Total	24,380,000	12,075,000
	6,877,568	Performance Share	es - Escrowed to
	09 Aug 20	18	
Number acquired		Shares	Options
	Direct	-	-
	Indirect	7,030,221	-
	Total	7,030,221	-
	a) 152,653 On Market purchase		
	b) 6,877,568 Performance Shares - Escrowed		
	to 09 Aug 2018		
Number disposed		Shares	Options
	Direct	-	-
	Indirect	-	-
	Total	-	-

<sup>+</sup> See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ul> <li>a) 152,653 shares \$82,127</li> <li>b) 6,877,568 shares - Milestone achieved, Escrowed to 09 Aug 2018</li> </ul>		
No. of securities held after change		Shares	Options
	Direct	35,000	12,075,000
	Indirect	31,375,221	-
	Total	31,410,221	12,075,000
Nature of change	a) 15	2,653 On Market	purchase
Example:	b) 6,877,568 Performance milestones		
on-market trade, off-market trade, exercise of options, issue	achieved – Shares Escrowed to 09		
of securities under dividend reinvestment plan, participation in buy-back	Aug 2018		

Part 2 – Change of director's interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<b>No. and class of securities to which</b> <b>interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

### Part 3 – +Closed period

Were the interests in the securities or	No
contracts detailed above traded	
during a +closed period where prior	
written clearance was required?	
If so, was prior written clearance	N/A
provided to allow the trade to	
proceed during this period?	
If prior written clearance was	N/A
provided, on what date was this	
provided?	



The CFO Solution

19 December 2016

<sup>+</sup> See chapter 19 for defined terms.